MEFV and amyloidosis: Our recommendations add to Butbul et al. [8]; who suggested considering discontinuation of colchicine in patients with attack-free period of at least 6 months, absence of 2 mutations in the MEFV gene, normal levels of acute-phase reactants, no family history of amyloidosis, and no proteinuria.